MPH Health Care

Earnings Release • Mar 14, 2014

News Details

Corporate | 14 March 2014 17:34

MPH Mittelständische Pharma Holding AG: Preliminary IFRS results 2013, sales of EUR 226.84 million, annual net income of EUR 7.49 million

MPH Mittelständische Pharma Holding AG / Key word(s): Preliminary Results/Final Results

14.03.2014 / 17:34

---

MPH Mittelständische Pharma Holding AG:

Preliminary IFRS results 2013, sales of EUR 226.84 million, annual net income of EUR 7.49 million

MPH Mittelständische Pharma Holding AG, Berlin (ISIN: DE000A0NF697), today reports its preliminary IFRS Group results for the financial year 2013.

In the financial year 2013 the preliminary IFRS sales amounted to approximately EUR 226.84 million and the preliminary IFRS consolidated profit was about EUR 7.49 million. The preliminary IFRS earnings per share reached about EUR 0.18.

IFRS Group sales increased by over 10 %, from EUR 205.71 million to around EUR 226.84 million compared to the previous year 2012. IFRS consolidated profit decreased from EUR 18.40 million to approximately EUR 7.49 million. In the previous year non-recurring profit from sales of property was generated.

The market value of the Pharma segment listed in the Entry Standard of the Frankfurt stock exchange, HAEMATO AG, rose by EUR 67.04 million in the year 2013. Thereby the MPH, as the majority shareholder, could build up substantial hidden reserves.

Under the umbrella of M1 Med Beauty AG, the healthcare field focuses on offers in the Lifestyle segment. Individual patient therapies, aesthetic surgeries and medical treatments are demanded by self-pay patients. Unlike in the pharmaceutical sector, the healthcare segment is not subject to legally mandated discounts and austerities. The investments in this area are being further expanded in 2014 and 2015. In the financial year 2014 sales of EUR 10 million is expected. Additional locations outside Berlin will support further growth.

The Management Board of the company will propose a dividend to the Supervisory Board and the shareholders after the approval of the final annual financial statements 2013.

About MPH Mittelständische Pharma Holding AG:

The company MPH Mittelständische Pharma Holding AG, based in Berlin, has strategically concentrated its activities on the growth segments Pharma and Healthcare. In the pharmaceutical sector, the corporate group makes a contribution towards cutting costs in the healthcare system with medicines manufactured on the basis of patent-free and patent-protected active substances for the therapy of chronic diseases. The field of healthcare offers a variety of services for individual patient therapies, aesthetic surgeries and other medical treatments.

MPH Mittelständische Pharma Holding AG is listed in the Entry Standard (Open Market) of the Frankfurt stock exchange.

Key figures for the share of MPH Mittelständische Pharma Holding AG:

Subscribed capital: EUR 41.167.155

Listed shares: Preference shares

Number of preference shares in circulation: 19.025.000

ISIN: DE000A0NF697

WKN: A0NF69

Stock symbol: 93MV

Contact: Linda Reichelt

MPH Mittelständische Pharma Holding AG

Fasanenstraße 77

D-10623 Berlin

Tel:+49 (0) 30 897308660 Fax:+49 (0) 30 897308669

E-Mail: ir@mph-ag.de Web: www.mph-ag.de

End of Corporate News

---

14.03.2014 Dissemination of a Corporate News, transmitted by DGAP – a company of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language:	English
Company:	MPH Mittelständische Pharma Holding AG
	Fasanenstraße 77
	10623 Berlin
	Germany
Phone:	030 / 897 308 660
Fax:	030 / 897 308 670
E-mail:	info@mph-ag.de
Internet:	www.mph-ag.de
ISIN:	DE000A0NF697
WKN:	A0NF69
Listed:	Freiverkehr in Berlin, Düsseldorf, Stuttgart; Frankfurt in Open Market (Entry Standard)

End of News	DGAP News-Service

- - -
257655  14.03.2014